Form 4: Kymera Therapeutics Director Bruce Booth Sells Shares Under 10b5-1 Trading Plans

Director Bruce Booth reports sales of Kymera Therapeutics (KYMR) common stock through pre-arranged 10b5-1 trading plans.

Summary

• Bruce Booth, a director of Kymera Therapeutics, reported the sale of common stock on March 14 and 15, 2024.
• The sales were executed under Rule 10b5-1 trading plans adopted on January 22, 2024, by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P.
• The transactions involved multiple sales at varying prices, ranging from approximately $39.13 to $41.73 per share.
• The sales were conducted through Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P., where Booth is a member of the general partner.
• Following the reported transactions, Booth indirectly holds 4,570,665 shares through Atlas Venture Fund X, L.P. and 806,697 shares through Atlas Venture Opportunity Fund I, L.P.

Sentiment

Score: 5

Explanation: The sentiment is neutral. The document simply reports stock sales by a director under a pre-existing trading plan, which is a routine event.

Risks

• The sales by a director could be perceived negatively by investors, although they were conducted under a pre-arranged trading plan.

Industry Context

Sales by insiders are a common occurrence, and the use of 10b5-1 trading plans is a standard practice to avoid accusations of trading on non-public information. The market will likely assess the sales in the context of the company's overall performance and future prospects.

Comparison to Industry Standards

• It is common for venture capital firms to distribute shares in their portfolio companies to their limited partners over time.
• The use of 10b5-1 trading plans is a standard practice among corporate insiders to sell shares without raising concerns about insider trading.
• Comparable companies with venture capital backing often see similar patterns of stock sales by directors affiliated with venture funds.

Stakeholder Impact

• The stock sales could have a minor impact on shareholder sentiment, but the existence of a 10b5-1 plan mitigates concerns about insider trading.

Key Dates